Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205266 | 0.85 | ADORA2A (0.63) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL6745798 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL6745804 | 0.77 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL7605264 | 0.77 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL1810956 | 0.76 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL169036 | 0.76 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL8893183 | 0.74 | ADORA1 (0.69) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| Hydrochloric Acid SCHEMBL11764383 | 0.71 | LMNA (0.50) | ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL2033894 | 0.71 | ADORA1 (0.60) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL11880590 | 0.70 | ADORA2A (0.56) | ADORA3ADORA2AADORA2BNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555775-B1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2555776-B1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND NON-SELECTIVE BETA-ADRENERGIC RECEPTOR BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| EP-2424546-B1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORP (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8470800-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| US-8440639-B2 | Combination compositions for reducing intraocular pressure | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2424546-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | Inotek Pharmaceuticals Corporation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110245193-A1 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010127210-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | ADORA3 3673/4885ADORA1 1957/4885ADORA2A 2480/4885 |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | ADORA2A, ADORA1, PDE6C | ADORA3 4/4885ADORA1 2/4885ADORA2A 1/4885 |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | ALDH1A2, GAP43, ALDH1A3 | ADORA3 226/4885ADORA1 101/4885ADORA2A 24/4885 |
| US-20110245193-A1 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 1/4885ADORA2A 2/4885 |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | ADORA3 3673/4885ADORA1 1957/4885ADORA2A 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.